



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/550,137	09/25/2006	Mats Inganas	HO-P02773US1	1324
29053	7590	04/27/2009	EXAMINER	
FULBRIGHT & JAWORSKI L.L.P			YANG, NELSON C	
2200 ROSS AVENUE				
SUITE 2800			ART UNIT	PAPER NUMBER
DALLAS, TX 75201-2784			1641	
			MAIL DATE	DELIVERY MODE
			04/27/2009	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/550,137	INGANAS ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Nelson Yang	1641	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 03 March 2009.  
 2a) This action is **FINAL**.                            2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1-17 and 19-29 is/are pending in the application.  
 4a) Of the above claim(s) 3-6, 22 and 23 is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 1,2,7-17,19-21 and 24-29 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on 21 September 2005 is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) Notice of References Cited (PTO-892)  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  
 3) Information Disclosure Statement(s) (PTO/SB/08)  
 Paper No(s)/Mail Date 1/31/06.

4) Interview Summary (PTO-413)  
 Paper No(s)/Mail Date. \_\_\_\_\_.  
 5) Notice of Informal Patent Application  
 6) Other: \_\_\_\_\_.

## **DETAILED ACTION**

### ***Election/Restrictions***

1. Applicant's election without traverse of compounds that exhibit a hydrophilic group and are water soluble, drawn to claim 2 in the reply filed on March 3, 2009 is acknowledged.
2. Claims 3-6, 22-23 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on March 3, 2009.
3. Claims 1, 2, 7-17, 19-21, 24-29 are currently under examination.

### ***Drawings***

4. The drawings are objected to as failing to comply with 37 CFR 1.84(p)(5) because they do not include the following reference sign(s) mentioned in the description: 101b-g, 103b-h, 104a, 104b, 104d-h, 106a-c, 106-e-h, 107a, 107c-h, 108a-d, 108f-h, 109a-c, 109e-f, 110b-h, 111a-g, 111h, 113b-f, 113h, 114a-d, 114f-h, 115a-f, 115h, 116b-h. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

***Claim Rejections - 35 USC § 112***

5. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claim 25 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

7. With respect to claim 25, it is unclear what the groups would be selected from other than streptavidin binding compounds, as the claim appears to be incomplete.

***Claim Rejections - 35 USC § 103***

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

9. Claims 1, 2, 8-17, 19-21, 25-27, and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Andersson et al. [US 2003/0053934] in view of Yager et al. [US 2003/0124623].

With respect to claims 1, 2, Andersson et al. teach a microfluidic device comprising a porous matrix placed in a microcavity or immediately downstream a microcavity, a packed bed of monosized particles in the microcavity (para. 0016), wherein the microcavity may further

comprise a solid phase with an immobilized affinity reactant (para. 0017). Andersson et al. fails to teach that the porous particles comprise a bed-preserving agent comprising a compound exhibiting a hydrophilic group and is water-soluble.

Yager et al., however, teach a microfluidic device comprising a microfluidic channel and storage area on a wall of the microfluidic channel with a solid reagent plug comprising a matrix, and a reagent having an affinity for binding to the analyte (para. 0011-0017). Yager et al. further teach that the matrix comprises preservatives such as trehalose and dextran (para. 0089), which are water soluble and exhibit hydrophilic groups. Yager et al. further teach that the once the reagent solutions are rendered solid and dry, the reagents are very robust with respect to storage (para. 0103-0104, 0109).

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to incorporate the bed-preserving agent of Yager et al. into the packed porous particles of Dourdeville in order to be able to render the reactants in the device of Andersson solid and in a dry state, such that it may be stored in a robust manner.

10. With respect to claim 8, 9, Yager et al. teach that the microfluidic device may be in a dry state (para. 0104). It is noted that claims 8 and 9 recite product by process limitations. "[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." *In re Thorpe*, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985).

11. With respect to claims 10-11, Andersson et al. teach a microfluidic device comprising a porous matrix placed in a microcavity or immediately downstream a microcavity, a packed bed of monosized particles in the microcavity (para. 0016), wherein the particles would be either swellable or non-swellable.

12. With respect to claims 12, 13, Andersson et al. teach an inlet microconduit connected to an inlet port via a volume defining unit that comprises a metering microcavity with valves associated with the outlet ports (para. 0065), wherein the inlet microconduits may simultaneously distribute liquid aliquots to several separate microchannel structures (para. 0066).

13. With respect to claim 14, Andersson et al. teaches that a microfluidic device comprising a metering system capable of delivering fluid and passive valves for controlling fluid flow (para. 0065-0068). Therefore, the metering system of Andersson et al. would have sufficient hydrophilicity for being filled by capillarity once an aqueous liquid enters the unit.

14. With respect to claim 15, fluid is delivered by centrifugal force (para. 0064).

15. With respect to claims 16, 17, 19-21, Andersson et al. teach that the immobilization of the reactant may comprise streptavidin and a biotinylated affinity reactant (para. 0090), wherein streptavidin would constitute the recited ligand L, and the biotinylated affinity reactant would constitute B-AC<sub>s</sub>. Since the binding is between streptavidin and biotin, the affinity constant would not be more than 10<sup>3</sup> larger than the affinity constant for streptavidin and biotin.

16. With respect to claims 25-27 Andersson et al. teach that the immobilization of the reactant may comprise streptavidin and a biotinylated affinity reactant (para. 0090).

17. With respect to claim 29, the antibodies of Yager et al. would have an affinity constant for formation of the complex between the antibody and a desired solute such as an analyte. Since

it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranged involves only routine skill in the art. *In re Aller*, 105 USPQ 233. Therefore, one of ordinary skill in the art would have found it obvious for the affinity constant for the formation of the complex to be no more than  $10^{-6}$  mole/L, through normal optimization procedures known in the art.

18. Claims 7, 24, and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Andersson et al. [US 2003/0053934] in view of Yager et al. [US 2003/0124623], as applied to claim 1 above, and further in view of Glezer et al. [US 2004/0189311].

With respect to claims 7, 24, 28, Andersson et al. and Yager et al. teach a matrix comprising reagents such as a preservation agent such as trehalose or dextran, but do not teach buffers such as phosphate buffers with a potassium counter-ion.

Glezer et al., however, teach dry reagent that may include a neutralizing reagent such as phosphate buffering agents (para. 0201), and further teach that this allows for the pH of the extracted sample to be brought to a value that is compatible with subsequent assay reactions carried out on the sample.

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention for the reagent of Andersson et al. and Yager et al. to comprise phosphate buffering agents, as suggested by Glezer et al., in order that the extracted samples could be prepared for subsequent assay reactions and analysis, and the use of a potassium buffer in the device of Andersson et al. would have yielded nothing more than predictable results to one of ordinary skill in the art at the time of the invention.

### ***Double Patenting***

19. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1, 8, 16-17, are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-14 of copending Application No. 10/550,182. In particular, the conflicting application recites two or more different sets of microchannel structures comprising a reaction microcavity in which there is a solid phase with an immobilized affinity ligand L directed toward a binder B (claim 1) and wherein the solid phase is in a dry state comprising one or more bed-preserving agents (claim 13). Although the conflicting application does not recite that the reaction microcavity is intended for retaining a solid phase material in the form of a wet porous bed, it would be capable of doing so, and therefore, would render the conflicting application obvious over the instant claims.

This is a provisional obviousness-type double patenting rejection.

***Conclusion***

20. No claims are allowed.
21. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nelson Yang whose telephone number is (571)272-0826. The examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mark Shibuya can be reached on (571)272-0806. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

22. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Nelson Yang/  
Primary Examiner, Art Unit 1641